LEADER 05215nam 22014413a 450 001 9910367748603321 005 20250203235425.0 010 $a9783039216536 010 $a3039216538 024 8 $a10.3390/books978-3-03921-653-6 035 $a(CKB)4100000010106231 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/56631 035 $a(ScCtBLL)f5e28124-59ab-4d1c-ae4e-3229c4ec396e 035 $a(OCoLC)1163840480 035 $a(oapen)doab56631 035 $a(EXLCZ)994100000010106231 100 $a20250203i20192019 uu 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPolymer Clay Nano-composites$fStefano Leporatti 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 210 1$aBasel, Switzerland :$cMDPI,$d2019. 215 $a1 electronic resource (246 p.) 311 08$a9783039216529 311 08$a303921652X 330 $aThis Special Issue focuses on the current state-of-the-art of "Polymer Clay Nano-Composites" for biomedical, anticorrosion, antibacterial, and other applications. Clay-polymer composite nanomaterials represent an emerging area of research. Loading polymers with clay particles essentially enhances the composite strength features. Of particular interest are different nano-assembly methods, such as silane mono and multilayers, polyelectrolyte layer-by-layer assembly, and others. An important development was reached for tubular and fibrous clay nanoparticles, such as halloysite, sepiolite, and imogolite. Polymer clay nanoparticles can be prepared as sheets with 1-nm thickness and width of a few hundred nm (e.g., kaolin and montmorillonite). Fibrous clays significantly reinforce the nano-composites in the assembly with biopolymers and other green polymers, leading to functional hybrid bio nano-composites. The scope of this Special Issue comprehensively includes the synthesis and characterization of polymer clay nano-composites used for several applications, including nano-clay polymer composites and hybrid nano-assemblies. 606 $aBiology, life sciences$2bicssc 610 $agraphene oxide 610 $apolysaccharide 610 $awater resistance 610 $ananocomposites 610 $alayered silicate 610 $apolyimide 610 $aintercalation 610 $abarrier 610 $acomposite 610 $aindentation recovery 610 $aionic network 610 $aorganically modified clays 610 $ananotechnology 610 $a2-polybutadiene 610 $adoxorubicin 610 $asericite 610 $aadsorption 610 $amorphology 610 $aphenyltrimethylammonium chloride 610 $asupercritical CO2 610 $ablowing agent 610 $ahalloysite nanotubes 610 $amechanical properties 610 $aglycerol 610 $aammonium persulfate 610 $aTGA 610 $a1 610 $ainterfacial interactions 610 $acarbon fibers 610 $ananocomposite materials 610 $asilica sol 610 $aN?-methylenebisacrylamide 610 $aintercalation stability 610 $apolymer composites 610 $aclay-polymer nanocomposites 610 $ain-situ intercalation 610 $aattapulgite/polypyrrole nanocomposite 610 $afish gelatin 610 $apolyacrylic acid 610 $afuzzy optimization 610 $aAFM 610 $avariable cost 610 $aorganic montmorillonite 610 $apositron annihilation 610 $awhey protein isolate 610 $ainterface 610 $aCTAB 610 $aN 610 $ahyaluronic acid 610 $aswelling capacity 610 $awater shutoff 610 $amontmorillonite 610 $asol-gel transition 610 $ain situ polymerization 610 $ahexadecyltrimethylammonium bromide 610 $aclay-amine interaction mechanisms 610 $agelation kinetics 610 $aFTIR 610 $asurface grafting 610 $aPareto set 610 $ala uptake and release 610 $apolyamines 610 $apolystyrene foam 610 $aCD44 receptor targeted 610 $atribological property 610 $apolyethylene oxide 610 $astructure effects 610 $acatalytic composite 610 $apolystyrene 610 $ananoclay 610 $athermal stability 610 $asacrificial bond 610 $aPd catalysis 610 $aradical polymerization 610 $adental resins 610 $areinforcing 610 $amontmorillonite clays 610 $acoatings 610 $aatrazine 610 $acellulose nanofibrils 610 $asoap-free emulsion polymerization 610 $aLAP 610 $adoubly functionalized montmorillonite 610 $adispersion 610 $aorgano-clays 615 7$aBiology, life sciences 700 $aLeporatti$b Stefano$01295569 801 0$bScCtBLL 801 1$bScCtBLL 906 $aBOOK 912 $a9910367748603321 996 $aPolymer Clay Nano-composites$93027388 997 $aUNINA LEADER 03247nam 2200829z- 450 001 9910557396203321 005 20210501 035 $a(CKB)5400000000041935 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69436 035 $a(oapen)doab69436 035 $a(EXLCZ)995400000000041935 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aIon Channels as Marine Drug Targets 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (134 p.) 311 08$a3-03943-797-6 311 08$a3-03943-798-4 330 $aMarine Drugs is glad to announce its first Special Issue book on "ion channels" related research: Under the great stewardship of the Guest Editor, Dr. Jean-Marc Sabatier, four advanced research articles and three comprehensive review papers were collected in the Special Issue "Ion Channels as Marine Drug Targets". Join us to explore the advanced research outcomes in this field: ?-Conotoxin RgIA and a potent analog, RgIA4, in treatment of pain; botulinum toxin-chitosan nanoparticles in treatment of atrial fibrillation; 27-amino acid (aa)-long ?-conotoxin TxVIA that modulates mammalian CaV3.x; first venomics study of Conus tulipa venom; review on marine toxins targeting Kv1 channels; review on synthetic approaches to zetekitoxin AB; and review on marine natural products and drug resistance in latent tuberculosis. The second edition of this Special Issue is open for submissions, we look forward to your contribution. 606 $aMedicine and Nursing$2bicssc 610 $aantiarrhythmics 610 $abioactives 610 $abotulinum toxin A1 610 $achemotherapy 610 $achitosan nanoparticles 610 $aconantokins 610 $aconotoxin 610 $aconotoxins 2 610 $aConus tulipa 610 $aelectrically induced arrhythmia 610 $aguanidine alkaloid 610 $aintraspecific variation 610 $aion channel modulators 610 $aKv1 610 $alatent TB 610 $amammalian NaV channel 610 $amarine anti-TB compounds 610 $amarine toxins 610 $amodulators 610 $aMTB 610 $anet hunting strategy 610 $aneuropathic pain 610 $anicotinic 610 $anirvana cabal 610 $apaclitaxel 610 $apharmacological models of arrhythmia 610 $apotassium channels 610 $aproteomics 610 $aPZA 610 $asaxitoxin 610 $asea anemone toxins 610 $aselective inhibitor 610 $asponges 610 $aT-type CaV3.2 610 $ataxane 610 $atranscriptomics 610 $aTxVIA 610 $avenomics 610 $avoltage-gated sodium channel 610 $azetekitoxin AB 610 $a?9?10 615 7$aMedicine and Nursing 700 $aSabatier$b Jean-Marc$4edt$01295534 702 $aSabatier$b Jean-Marc$4oth 906 $aBOOK 912 $a9910557396203321 996 $aIon Channels as Marine Drug Targets$93023587 997 $aUNINA LEADER 03629nam 22006255 450 001 9910300085703321 005 20200705084100.0 010 $a3-642-39590-2 024 7 $a10.1007/978-3-642-39590-1 035 $a(CKB)3710000000088889 035 $a(EBL)1697761 035 $a(OCoLC)871206684 035 $a(SSID)ssj0001187489 035 $a(PQKBManifestationID)11695504 035 $a(PQKBTitleCode)TC0001187489 035 $a(PQKBWorkID)11257157 035 $a(PQKB)10724968 035 $a(MiAaPQ)EBC1697761 035 $a(DE-He213)978-3-642-39590-1 035 $a(PPN)176748229 035 $a(EXLCZ)993710000000088889 100 $a20140213d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aRare Lymphomas /$fedited by Martin Dreyling, Michael E. Williams 205 $a1st ed. 2014. 210 1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2014. 215 $a1 online resource (365 p.) 225 1 $aHematologic Malignancies,$x2197-9766 300 $aDescription based upon print version of record. 311 $a3-642-39589-9 320 $aIncludes bibliographical references at the end of each chapters. 327 $aI General:  Pathology -- Cytogenetics -- Molecular Genetics -- Signal Pathways -- II Disease-specific: T-NHL: Acute T-cell leukemia -- Anaplastic lymphoma -- Nasal/NK-cell lymphoma -- Cutaneous T-cell lymphoma -- B-NHL: Adult Burkitt -- Primary Mediastinal Lymphoma -- CNS Lymphoma -- HIV-Associated lymphoma -- Marginal Zone Lymphoma -- MALT -- MCL -- Waldenstroem -- PLL -- Llymphocyte Predominant Hodgkin -- Cutaneous B-cell lymphoma. 330 $aThe past decade has witnessed tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma as well as in understanding of the underlying molecular pathogenesis. Optimal treatment strategies are now based not only on accurate diagnosis but also on thorough evaluation of clinical and molecular risk factors. Even more importantly, molecular targeted approaches have been shown to be effective in the treatment of distinct lymphoma subtypes. Against this background, clinical management of especially the rare lymphomas remains a challenge for the general oncologist.   This book provides a comprehensive overview of current treatment strategies in these rare lymphoma subtypes. Experts in the field from around the world describe the histomorphology in a clinically relevant manner, consider the role of risk factors in detail, and discuss the spectrum of therapeutic approaches. Special emphasis is placed on the translation of molecular science into clinical care, and a disease-specific algorithm is proposed for each entity. This book will prove an excellent resource for both experienced and inexperienced practitioners. 410 0$aHematologic Malignancies,$x2197-9766 606 $aHematology 606 $aOncology 606 $aHematology$3https://scigraph.springernature.com/ontologies/product-market-codes/H3307X 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 615 0$aHematology. 615 0$aOncology. 615 14$aHematology. 615 24$aOncology. 676 $a616 676 $a616.99/446 676 $a616.9944 702 $aDreyling$b Martin$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aWilliams$b Michael E$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300085703321 996 $aRare Lymphomas$91522245 997 $aUNINA